North Star Asset Management Inc. Acquires New Shares in Edwards Lifesciences Corporation $EW

North Star Asset Management Inc. acquired a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 71,575 shares of the medical research company’s stock, valued at approximately $6,475,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $25,000. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences in the first quarter valued at $25,000. MV Capital Management Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth about $26,000. RMG Wealth Management LLC acquired a new position in Edwards Lifesciences during the 1st quarter worth approximately $26,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $27,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $89.97 on Friday. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $89.48 and a two-hundred day moving average price of $84.99. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a market capitalization of $51.81 billion, a P/E ratio of 51.71, a price-to-earnings-growth ratio of 2.38 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the previous year, the company posted $0.67 EPS. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,857 shares of company stock valued at $170,305 over the last ninety days. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on EW shares. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Citigroup lifted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Finally, Truist Financial boosted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.